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The hepatitis B surface antigen (HBsAg)' is present both on the envelope of
the intact virion and as free, circulating, 22-nm particles in the serum ofinfected
patients. The two major polypeptides of HBsAg, p25 and its glycosylated form
gp28, have identical amino acid sequences encoded by the S gene of the hepatitis
B virus (HBV) genome. Recently (1), an additional higher mol wt glycoprotein
component ofHBsAgwasidentifiedas gp33/gp36. The p33 polypeptide contains
the sequence of p25 and has 55 additional amino acids at the amino terminus,
encoded by the pre-S(2) region of the HBV genome (1, 2). In support of this,
Neurath et al. (3) synthesized a peptide encompassing the 26 NH2-terminal
amino acids of the pre-S(2) region, and antibodies to this peptide (p120-145)
reacted with p33-containing particles (HBsAg/p33) but not with particles lacking
the pre-S(2) region (HBsAg/p25). It has also been shown (4) that antibodies to
p120-145 compete with anti-native pre-S(2)-specific antibodies for the same or
closely related binding site(s) on native HBsAg/p33 particles. Additionally the
native pre-S(2) region, expressed on recombinant HBsAg/p33 particles, has been
shown (4, 5) to be significantly more immunogenic (at the B and T cell levels)
than the S region of HBsAg. Moreover, independent H-2-linked regulation of
the pre-S(2) and S region immune responses decreases the probability of genetic
nonresponsiveness after HBsAg/p33 immunization (5). For these and other
reasons, the inclusion of pre-S(2)-bearing polypeptides in future HBsAg particle
vaccines has been suggested (3-7). These observations, and the fact that the
synthetic peptide p120-145 was also reported (3) to be highly immunogenic in
animals, prompted us to examine T cell recognition of this pre-S(2)-specific
synthetic peptide in terms of fine specificity, H-2-linked genetic influences,
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comparison to antibody binding, and relevance to T cell recognition ofthe native
protein .
The results of this study indicate that the predominant T and B cell recognition
sites on the synthetic pre-S(2) peptide are nonoverlapping. T cell recognition is
focused on the NH2-terminal sequence, and antibody (B cell) recognition is
focused on the COOH-terminal sequence . The fine specificity of T cell recog-
nition of p120-145 was defined by a single amino acid substitution. The fine
specificity of B cell recognition has also been investigated and is the subject of
another study.2 The immune response to the pre-S(2) synthetic peptide p120-
145 is regulated by H-2-linked genes, but the pattern of H-2 restriction differed
from that of the native pre-S(2) region response. This finding, and the inability
of p120-145-primed T cells to recognize native pre-S(2) region protein indicate
that, in contrast to the B cell response, p120-145 does not represent a native
pre-S(2) region T cell recognition site. However, p120-145 does represent a
totally synthetic immunogen possessing distinct T and B cell determinants, and
the T cell recognition site is capable of priming T cell help for antibody
production, which is crossreactive with the native pre-S(2) region on HBsAg/p33
particles. This system offers evidence that a synthetic T cell site coupled to a
synthetic B cell site can comprise a functional immunogen (vaccine) without the
necessity of a heterologous protein carrier to elicit T cell helper function .
Materials and Methods
Mice. C57BL/10 (1310), B10.D2, B10 .BR, B10.S, B10.M, C3H.Q, C3H, and SJL/J
murine strains were obtained from the breeding colony at the Research Institute of
Scripps Clinic. Female mice, 6-8 wk of age at the start of the experiments, were used in
all studies.
HBsAg Particles and Synthetic Peptide Analogs of the Pre-S(2) Region.
￿
Recombinant
HBsAg particles derived from Chinese hamster ovary (CHO) cells transfected with a
plasmid containing the S gene and the pre-S region of HBV (7) were provided by P.
Tiollais (Pasteur Institute, Paris). The CHO-derived particles are composed of the S-
encoded p25 plus the pre-S(2) and S-encoded p33 in a ratio of -3:1 (7), and are herein
designated as HBsAg/p33. The peptides were synthesized by the Merrifield solid-phase
method, and were subjected to HPLC on a C18 reverse-phase column. All the peptides
used eluted as a single major peak (>90%). Synthetic peptides were provided by the
peptide laboratory of the Biotechnology Center, Inc. (Sorrento Valley, CA).
The amino acid sequence of the pre-S(2) region from residues 120-145 is illustrated
in Fig. 1 . Sequence variation relative to three HBsAg subtypes ayw (8), adw2 (9), and adw
(10) are shown . The peptides synthesized and used in this study are also depicted in Fig.
1 . The first methionine, which represents the NH2-terminus of p33, is labelled 120, since
it can be preceded by 119 residues comprising the pre-S(1) region yielding a polypeptide
of 39 kD (11).
Measurement of In Vivo Antibody Production.
￿
Pooled murine sera were evaluated for
antibody in an indirect, solid-phase RIA using solid-phase HBsAg/p33 (0.1 Eeg/well) or
synthetic peptides (1-2 Ag/well), and goat anti-mouse IgG, and developed with an
'2sI-
labelled, affinity-purified swine anti-goat Ig as described (12). Data are expressed as
antibody titer representing the highest dilution to yield three times the counts of preim-
munization sera. Mice were immunized for determination of in vivo antibody production
by i.p. injection of either 1 .0 gg of HBsAg/p33 or 100 wg of synthetic peptide emulsified
2 Milich, D. R., A . McLachlan, F. V. Chisari, T. Nakamura, G. B. Thornton. Two distinct but
overlapping antibody binding sites in the pre-S(2) region of HBsAg localized within I I continuous
residues. Manuscript submitted for publication.534
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SUBTYPE
ayw M0WNSTTFH0TL00PRVRGLYFPAGG
adw= ------A--------------L----
adw ------AL--A----------L----
Results
FIGURE 1 .
￿
The aminoacid sequence of residues 120-145 of the pre-S(2) region of HBsAg.
Sequences of the ayw, adw2, and adw subtypes of HBV are shown. The sequences are presented
in the one-letter code system, a dashed line represents a residue unchanged from the ayw
sequence. Also depicted are the synthetic peptide analogs used in this study.
in CFA. Sera was collected 24 d after primary immunization, and 2 wk after secondary
immunization with a half dose of antigen in IFA .
T (.'ell ProliferativeAssay.
￿
Groups of mice were primed with either 4,ug of HBsAg/p33
or 100 jug of synthetic peptide in CFA by hind footpad injection. 5-10 d after immuni-
zation, draining popliteal lymph node (PLN) cells were harvested, and 5 x 105 cells in 0.1
in] of Click's medium (13) were cultured with 0.1 ml of medium containing HBsAg/p33,
various synthetic peptides, or medium alone. Cells were cultured for 96 h at 37°C in a
humidified 5% C02 atmosphere, and during the final 16 h, 1 uCi of ['H]thymidine (6.7
Ci/mmol; New England Nuclear, Boston, MA) was added. The cells were then harvested
onto filter strips for determination of [sH]TdR incorporation. The data are expressed as
cpm corrected for background proliferation in the absence of antigen (Ocpm). The T cell
nature of the proliferation was confirmed in selected experiments by concurrently analyz-
ing antigen-specific, dose-dependent, IL-2 production in 24-h supernatants as described
(14). Since the PLN proliferative responses always correlated with IL-2 production, only
the proliferative responses are reported.
TheAnti-Peptide (p120-145) Pre-S(2) Response Is H-2 Restricted, But in a Manner
Distinctfrom H-2 Restriction of Response to Native Pre-S(2) Region. Since we had
previously shown (5) that the immune response to the native pre-S(2) region was
regulated by H-2-linked genes and was mediated at the T cell level, we wished
to determine whether the response to the synthetic pre-S(2) peptide was similarly
regulated. A panel of B10 H-2-congenic strains was immunized i.p. with either
HBsAg/p33 particles or with the free pre-S(2)-specific synthetic peptide p120-
145, both of the ayw subtype (Fig. 2) . The anti-pre-S(2) region responses were
analyzed by RIA using p120-145 as the solid-phase ligand. Anti-HBs/p33 sera
were tested 24 d after primary immunization (pre-S(2) response predominates
over the S response at this time [4]), and antipeptide sera were tested after
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FIGURE 2.
￿
Distinct H-2 restriction of the immune responses to the native pre-S(2) region on
HBsAg/p33 particlesand the pre-S(2) region synthetic peptide p120-145. Groups of five mice
from a series of H-2-congenic strains were immunized with either HBsAg/p33 ay (top), or
p120-145/ay (bottom). Serum samples were pooled and pre-S(2)-specific antibody production,
determined by RIA using p120-145/ay as the solid-phase ligand, was analyzed afterprimary
immunization with HBsAg and secondary immunization with p120-145. The results are
expressed as a percent of the highest responder strains response. (i.e., B10 immunized with
HBsAg/p33, 1:4,096; BlO.BR immunized with p120-145, 1:80,000). The H-2 haplotype of
each strain is shown.
secondary immunization . As illustrated in Fig. 2, HBsAg/p33 immunization
elicited pre-S(2)-specific antibody in all strains except B10.M, and the hierarchy
of responsiveness was as follows B10 > B10.D2 > B10.S > B10.BR, indicating
that the anti-pre-S(2) response is influenced by H-2-linked genes. The results of
immunization with p120-145 also indicated the influence of H-2-linked genes on
the antibody response, however, the order of responsiveness BIO.BR > B10,
B10.S > BIO.D2, B10.M (nonresponders) was significantly different as compared
with HBsAg/p33 immunization. For example, the B10.D2 strain produced anti-
p120-145-specific antibody after HBsAg/p33 immunization, and yet is a total
nonresponder to the p120-145 peptide upon immunization with p120-145. In
contrast, the B10.BR strain is a low responder to p120-145 after HBsAg/p33
immunization, whereas this strain is the highest responder after p120-145 im-
munization (i.e., 1:80,000 titer).
The C3H.Q (H-29) strain showed the highest response to p120-145 immuni-
zation, with a secondary titer of 1 :1 .2 X 106 (see Fig. 4). Therefore, the C3H.Q
strain was used in many of the experiments described below.
Since H-2 restriction is determined at the T cell level, these results argue very
strongly that T cell recognition sites on the native pre-S(2) region (i.e., residues
120-174) need not be identical to those recognized when the synthetic peptide
p120-145 is the immunogen. In the case of the BIO.D2 strain, which does show
a pre-S(2)-specific, T cell proliferative response after HBsAg/p33 immunization
(5) and possesses p120-145-specific B cell clones, it is clear that the antibody
response to the pre-S(2) region is not mediated by T cell recognition of the p120-
145 sequence, since this strain is nonresponsive to immunization with p120-145 .
In other words, p120-145 does not contain a T cell determinant recognizable in
the context of the H-2d haplotype (BALB/c mice [H-2d
] are also nonresponsive536
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FIGURE 3. The C3H.Q T cell proliferative response after p120-145/ay immunization. A
group of C3H.Q mice were immunized with 100 jug ofp120-145/ayw, and T cell proliferation
specific for the indicated peptides was determined. T cell proliferation was determined by
incorporation of [sH]thymidine and expressed as cpm adjusted for background (0 cpm).
Background proliferation in the absence ofantigen ranged from 1,000 to 4,000 cpm.
to this peptide) . Consistent with this is the finding that the B10.D2 and BALB/c
strains primed with p120-145 did not show a p120-145-specific T cell prolifer-
ative response (data not shown).
T Cell Recognition ofp120-145 Focuses on the NH2 Terminus, Whereas B Cell
(antibody) Recognition Focuses on the COOH-terminal Sequence. To examine the
fine specificity of T and B cell (antibody) recognition of the pre-S(2) region
synthetic peptide p120-145, C3H.Q mice were immunized with p120-145/ayw,
and the specificity of the in vitro proliferative T cell response and the in vivo
antibody response were determined. For this purpose an NH2-terminal peptide
(p120-132), a COOH-terminal peptide (p133-145), and an overlapping peptide
(p128-138) were synthesized (Fig. 1). To determine possible subtype-specific
influences, pl20-145/adw2 was also synthesized. Note that the adw2 subtype
differs from the ayw subtype at amino acid positions 126 and 141 .
After p120-145/ay priming, p120-145/ay and p120-132/ay were capable of
eliciting significant proliferative T cell responses, whereas p133-145/ay was
minimally reactive, and p128-138 was totally nonstimulatory (Fig. 3). The fact
that there was a less than twofold difference between the proliferative response
of p120-145/ay-primed T cells induced by p120-145 and p120-132 through
most of the dose-response curve pinpoints a predominant T cell recognition site
to the N142-terminal 120-132 residues. Furthermore, the minimum degree of
crossreactivity between p120-145 of the ayw vs. the adw2 subtype indicated that
residue 126 was critical to T cell activation. Peptide p120-145-primed T cells
were also challenged in vitro with native HBsAg/p33 particles, which did not
elicit a proliferative response. The reciprocal experiment, priming with
HBsAg/p33 and challenging with p120-145, was also negative (data not shown).MILICH ET AL .
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FIGURE 4 .
￿
In vivo antibody production after p120-145/ay immunization in C3H.Q mice. A
group of 5CsILQmice were immunized with 100 Ag of p120-145/ayw, and sera were collected
24 d after primary immunization (1 °) and 2 wk after secondaryimmunization (2 °) with a half-
dose of antigen . Sera were pooled and analyzed by RIA for binding to the indicated solid-
phase ligands . The results are expressed as themaximum sera dilution to yield three times the
counts of preimmunization sera (titer) .
This observation confirms the notion that p120-145 need not represent theT
cell recognition site on the native pre-S(2) region, as suggested by the H-2
restriction data .
The specificity of the antibody response after p120-145/ay immunization is
presented in Fig. 4 . Sera were tested 2 wk after primary and secondary immu-
nizations . The antibody response to p120-145 differed from the T cell response
in several significant ways . First, anti-p120-145 bound native HBsAg/p33 almost
to the same extent as the homologous peptide (anti-native HBs/p33 also binds
p120-145 very efficiently [4]) . Second, the majority of antibody bound to the
COOH-terminal p133-145 sequence (1 :409,600), as opposed to p120-132
(1 :4096), which elicited the greatest T cell proliferative response . Third, a small
percentage of antibody bound p128-138, whereas this peptide did not activate
p120-145-primed T cells. Finally, anti-p120-145/ayw antibody showed a high
degree of crossreactivity for the p120-145/adw2 subtype peptide, in contrast to
the T cell response . These data indicate that p133-145 represents the dominant
antibody binding site on p120-145 as well as a major binding site on native
HBsAg/p33, and p120-132 represents the dominant T cell recognition site on
the synthetic peptide p120-145, but not with respect to the native protein, at
least in the C3H.Q strain .
Since we had identified dominant, independentTandB cell epitopes on p120-
145, we also wished to compare the relative immunogenicities of the T cell
epitope (p120-132) and theB cell epitope (p133-145) with the intact immunogen
(p120-145) . Although, p120-132 induced a primary (4-wk) antibody response
reactive with its own sequence, it did not induce a response crossreactive on
native HBsAg/p33 (Table 1) . Peptide 133-151 was used to represent the B cell
epitope in this experiment, and elicited a primary antibody response that reacted
equivalently with native HBsAg/p33 and the p133-145 sequence (i .e ., 1 :10,240) .
However, these responses were quite low as compared with the response elicited
by p120-145, which possesses both T and B cell determinants (Table 1) .
A Single Amino Acid Substitution Defines T Cell Recognition of Synthetic Peptide
120-132 . Because p120-132/ay efficiently induced proliferation of p120-
145/ay-primed T cells, and because subtype appeared important, C3H.Q mice538
￿
NONOVERLAPPING SYNTHETIC T AND B CELL DETERMINANTS
TABLE I
Comparative Immunogenicity of Uncoupled Pre-S(2) Region Synthetic
Peptides in C3H.QMice
Immunogen
Antibody titer (reciprocal) and specificity
p120-145 pl20-132 pl33-145 HBsAg/p33
p120-145 512,000 5,120 256,000 160,000
p120-132 160 640 0 0
p133-151 10,240 0 10,240 10,240
Groups of five mice were immunized with 100,ug i.p . of each peptide of
the ayw subtype in CFA, and sera were collected and pooled 4 wk after
primary immunization .
FIGURE 5 .
￿
The C3H.Q T cell proliferative response after p120-132 immunization . Groups
of 3 C3H.Q mice were immunized with 100 jug of either p120-132/ayes (a) or pl20-l32/adw2
(b), andT cell proliferation specific for the indicated peptides determined as described in Fig .
3 .
were primed with either the ayw or the adw2 subtype sequence of p120-132, and
T cells were challenged in vitro with 120-132/ay, 120-145/ay, 120-132/ad, or
120-145/ad . The ayw and adw2 sequences of 120-132 differ only at residue 126
(threonine, alanine, respectively) . T cells primed with the ayw sequence of 120-
132 proliferated in response to p120-132/ay and p120-145/ay, but only margin-
ally to the adw2 sequences (66.6-fold difference) (Fig . 5a). In the reciprocal
experiment, T cells primed with the adw2 sequence of 120-132 proliferated
when challenged with p120-132/ad and p120-145/ad, and were only minimally
reactive to the ayw sequences (32-fold difference) (Fig. 5b) . These data indicate
the importance of residue 126 in the T cell recognition of 120-132, and show
that a single amino acid can dramatically affect the fine specificity of T cell
recognition, since the ayw and adw2 sequences are relatively noncrossreactive .
To further define the T cell recognition site, C3H.Q mice were primed with
p120-131 of the adw sequence, which differs from both the ayw and adw2
sequences at residues 127 and 130, and lacks residue 132 (Fig . 1) . As illustrated
in Fig . 6, the adw and adw2 sequences were quite crossreactive, and the ayw
sequence was nonstimulatory for p120-131/adw-primed T cells . This finding
emphasizes the importance of residue 126, and suggests that residues 127, 130,
and 132 are not critical toT cell recognition of the p120-132 sequence .0
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FIGURE 6. The influence of subtype on the C3H.Q T cell proliferative response after
immunization with p120-131/adw. A group of three C3H.Q mice was immunized with 100,ug
ofp120-131/adw,andTcell proliferation inducedby thehomologous peptide(p 120-131/adw),
p120-132/adw2, and p120-132/ayes was determined as described in Fig. 3.
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FIGURE 7.
￿
Strain variability of the p120-132-specific T cell response after p120-145 im-
munization. Groups of three mice each of the indicated strains were immunized with 100 Ag
of p120-145/ayw, and T cell proliferation induced by pl20-132/ayw was determined as
described in Fig. 3.
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To examine whether T cell recognition of p120-132 was unique to the C3H.Q
strain, several other murine strains were immunized with p120-145/ayw, and T
cell proliferative responses specific for p120-132/ayw were determined (Fig. 7) .
All strains except B10 showed a subtype-dependent T cell proliferative response
to the immunogen, p120-145/ayw (data not shown). Although the C3H.Q strain
responded best to p120-132, all strains tested except the B10 strain (SJL/J,540
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TABLE II
Reactivityof Anti-p120-132/ay with Subtype Sequences
Sera were collected 4 wk after primary immunization and 2 wk after secondary
immunization.
B10.S, B10.BR, and C3H) showed a significant response to p120-132 after p120-
145 priming. Therefore, it appears that p120-132 can be recognized in the
context of the H-2y, H-25, and H-2k haplotypes, but not the H-26 haplotype.
Interestingly, B10 strain T cells immunized with pl20-145/ayw proliferated
equivalently to the adw2 and ayw subtype sequences of p120-145, and B10 was
the only strain that showed at least a marginal response to challenge with native
HBsAg/p33 (data not shown). The absence of a subtype-specific response indi-
cates that residue 126 is not critical to T cell recognition of p120-145 in the B10
strain.
We also wished to examine the fine specificity of in vivo antibody production
to p120-132 . Therefore, C3H.Q mice were immunized with pl20-132/ayw and
primary and secondary sera were analyzed for reactivity on solid-phase p120-
132/ayw, 120-132/adw2, and 120-131/adw (Table 11). In contrast to T cell
recognition, antibody to p120-132/ayw crossreacted with the adw2 sequence quite
well (twofold difference), indicating that the alanine-for-threonine substitution
at residue 126 did not severely affect the antibody binding site on p120-132.
Conversely, anti-p120-132/ay did not bind well to p120-131/adw, indicating that
the COOH-terminus of p120-132 is involved in antibody recognition. For
comparison, primary anti-p120-145/ayw serum was also examined for fine spec-
ificity, and gave similar results, except that the more immunogenic p120-145
elicited a greater response to all antigens (Table 11). Note that, at the T cell
level, the adw2 and adw sequences were very crossreactive. These data suggests
that, even with respect to a synthetic peptide as small as 13 amino acids, T and
B cell recognition sites can be distinct.
NH2-terminal Peptide 120-132 Can Prime T Cell Helpfor COOH-terminal Peptide
133-145. Because it appeared that distinct T cell and B cell epitopes existed on
p120-145, we examined the ability of the isolated T cell site (p120-132) to prime
T helper cell function for the dominant antibody binding site on p120-145
(p133-145). C3H.Q mice were either primed with 100 tag of p120-132/ay in CFA
or injected with CFA alone, and 4 wk later were boosted with either 100 Ag of
p120-145/ay or 1 .0 jug of HBsAg/p33/ay in incomplete adjuvant. Sera were
analyzed for an IgG response specific for various determinants 1 wk after the
boost. As illustrated in Table III, p120-132 was capable of priming the anti-
p133-145 response after the boost with p120-145 . Unprimed mice did not
produce anti-pre-S(2) of any specificity, however, p120-132-primed mice pro-
duced an IgG titer of 1 :640 specific for the p133-145 peptide. The other solid-
phase antigens all possess the 120-132 sequence, so it is difficult to discriminate
Antibody titer (reciprocal) and specificity
Immunogen Immunization
p120-132/ayw p120-132/adw2 p120-131/adw
p120-132/ay Primary 1,280 640 80
Secondary 5,120 2,560 40
p120-145/ay Primary 10,240 5,120 640MILICH ET AL.
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TABLE III
Ability ofp120-132 to Prime In Vivo Antibody Production
Groups of four C3H.Q mice each were primed with 100 Ag of p120-132 in CFA
administered i.p., or with CFA alone (-), and 4 wk later, they were boosted with either
100 hg of p120-145 or 1 tcg of HBsAg/p33 in incomplete adjuvant. Mice were bled I
wk after the boost, and sera were assayed for IgG specific for the indicated antigens.
All antigens were of theaywsubtype.
anti-p133-145 from anti-p120-132 on these ligands. Although p120-132 primed
the anti-p133-145 response after a p120-145 boost, p120-132 did not prime any
pre-S(2)-specific response after the HBsAg/p33 boost (Table 111). This finding
confirms that p120-132-primed C3H.Q T cells do not recognize this sequence
on the native protein, which is consistent with the lack ofa HBsAg/p33-induced
proliferative response, and the H-2 restriction data.
Discussion
This study was undertaken to examine T cell recognition of an HBsAg, pre-
S(2) region synthetic peptide (p120-145) previously shown (3) to be highly
immunogenic and to represent a dominant antibody binding site on the native
pre-S(2) region (3, 4). The results of this study indicate the following: (a) the
anti-p120-145 response is regulated by H-2-linked genes, but differs from the
pattern of H-2 restriction observed for the native anti-pre-S(2) response; (b)
nonoverlapping, dominant Tand B cell recognition sites were identified on the
synthetic peptide 120-145; (c) the fine specificity of Tcell recognition of p120-
145 is defined by a single amino acid substitution; (d) the synthetic peptide
containing both Tand B cell determinants is highly immunogenic in responder
strains, whereas separate T cell or B cell peptide determinants are minimally
immunogenic; and (e) the synthetic T cell recognition site can prime T cell help
for antibody production to the synthetic B cell site, which is crossreactive with
the native pre-S(2) region .
Previous work (4, 5) showed the influence of H-2-linked genes on antibody
production and the T cell proliferative response to the native pre-S(2) region of
HBsAg. The order of responsiveness at the antibody level correlated with the T
cell proliferative responsesand was as follows: B10 > B10.D2 > B10.S > B10.BR
> B10.M (nonresponder). Since antibody specific for the native pre-S(2) region
and the synthetic peptide are highly crossreactive (4), it was possible to compare
the influence of H-2-linked genes on in vitro antibody production to the native
pre-S(2) region vs. the synthetic peptide 120-145. Although the pre-S(2) region
exists on a larger polypeptide (p33), which includes S region antigenic determi-
nants, the pre-S(2)-specific antibody and T cell responses have been shown (4,
Priming
immunization Boost
Antibody titer (reciprocal) and specificity
p120-145 p120-132 p133-145 HBsAg/p33
p120-132 - 160 640 0 0
- p120-145 0 0 0 0
p120-132 p120-145 2,560 5,120 640 1,280
- HBsAg/p33 320 40 160 160
p120-132 HBsAg/p33 640 640 40 320542
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5) to be of greater magnitude, precede in time, occur at a lower HBsAg dose
and be independently regulated as opposed to the S region-specific responses.
Therefore, genetic and other influences of the immune response to the S region
on the pre-S(2) region response can be discriminated and/or negated. The order
of responsiveness to p120-145 after immunization with the unconjugated ho-
mologous synthetic peptide p120-145 is B10.BR > B10, B10.S > B10.D2, B10M
(nonresponders) was clearly different from that observed after immunization
with pre-S(2) region-containing particles (HBsAg/p33). For example, the
B10.D2 strain produced anti-p120-145 after immunization with HBsAg/p33,
but was totally nonresponsive when immunized with p120-145 . Sincethe B10.D2
and BALB/c (both H-2d) strains are very responsive at the T cell level to the
native pre-S(2) region (5) but not to p120-145, it is obvious that p120-145 does
not represent the T cell determinant on the pre-S(2) region recognized by H-2d
bearing strains. Conversely, the B10.BR strain is a low responder when immu-
nized with the intact pre-S(2) region, and a high responder after p120-145
immunization. This finding suggests that Suppressor-activating determinants may
exist elsewhere on the native protein, which downregulate the p120-145-specific
response. Suppressor mechanisms have been implicated (14, 15) in the low-
responder status of the B10.BR strain after HBsAg/p25 immunization. These
results indicate that the immunogenicity of a constituent peptide, even though
that peptide represents a dominant antibody binding site on the native protein,
is not necessarily predictive of the immunogenicity of the intact molecule, and
vise versa. Furthermore, immunogenicity of a carrier-free peptide is critically
dependent on T cell helper function, which is regulated by H-2-linked genes.
Since the pattern of H-2 restriction was different after peptide or HBsAg/p33
immunization, it is clear that T cell recognition sites on p120-145 need not be
identical to those recognized when the native pre-S(2) region is the immunogen.
This was more directly shown by the observation that p120-145-primed T cells
from most strains did not recognize the native pre-S(2) region upon in vitro
challenge, and did not prime an in vivo anti-pre-S(2) antibody response after a
boost with HBsAg/p33. This was true even in the C3H.Q strain, which is a high
responder in terms of anti-p120-145 antibody production whether immunized
with p120-145 or HBsAg/p33. Therefore, a constituent peptide may represent
an antibody binding site on the native protein, but lack a T cell recognition site
relevant to the native protein. We have analyzed numerous nonoverlapping pre-
S(2) region synthetic peptides encompassing the entire 55 amino acid region
without successfully identifying a synthetic T cell site that activates HBsAg/p33-
primed T cells. We are convinced that this is not due to antigen processing
characteristics or other unknown influences unique to this particulate antigen,
since we have been successful in delineating a native T cell recognition site in
the pre-S(1) region of the p39 polypeptide of HBsAg using similar techniques
(16). Likewise, numerous investigators (17-19) have localized T cell recognition
sites on other native protein antigens using synthetic peptides.
Although the 120-145 sequence of the pre-S(2) region does not appear to have
a T cell recognition site relevant to the native protein in most strains, a dominant
rf cell determinant, relevant to p120-145 immunization, was identified on the
NHz-terminus of p120-145 (p120-132). This T cell determinant does notoverlapMILICH ET AL.
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with the dominant antibody (B cell)-binding site on the COOH-terminus (p133-
145) of p120-145 . In the C3H.Q strain, the p120-132 sequence represents the
dominant T cell recognition site on p120-145, as shown by its ability to activate
p120-145-primed T cells approximately as well as the immunogen, and by the
ability of p120-132 to prime T cell help for antibody production to the p133-
145 sequence. The fine specificity of T cell recognition of p120-132 was further
refined by examining the influence of subtype. The ayw and adw2 subtypes differ
by a single amino acid substitution at residue 126 in the 120-132 sequence;
nevertheless, p120-132/ayzu-specific T cells were virtually noncrossreactive on
p120-132/adw2, and reciprocally, p120-132/adw2-specific T cells did not cross-
react with p120-132/ayw. The trimolecular complex model of T cell recognition
proposed by Heber-Katz et al. (20) suggests that class II-encoded la molecules
and antigen physically interact at one subsite on the antigen (agretope), and
another subsite on the antigen contacts the T cell receptor (epitope). With
respect to the peptide antigen p120-132, a single amino acid substitution at
residue 126 drastically reduced T cell activation, andfurthermore, immunization
with the substituted analog elicited a comparable T cell response specific for the
substitution . In the context of the trimolecular model, these results are consistent
with residue 126 representing a contact site with the T cell receptor (epitope)
(18). The fact that both peptides were equivalently immunogenic in the C3H.Q
(H-29) strain, regardless of the threonine to alanine substitution, suggests that
the agretope would reside in a shared sequence outside residue 126. If this were
true, the two peptides should compete for the same la-binding site (21, 22), and
p120-132/adw2 would inhibit the activation of p120-132/ayw-primed T cells
elicited by p120-132/ayw. However, no such inhibition occurred (our unpub-
lished observation), suggesting that residue 126 may be involved in the interac-
tion with la (i.e., agretope). In this case, both substitutions at 126 must be
permissable in the context of Ia9 (i .e., immunogenic), and the threonine vs.
alanine la9 interactions variably influence the trimolecular complex to the extent
that at least two noncrossreactive T cell clones would be generated to a single
primary sequence (epitope). Since agretope inhibition experiments have not been
universally successful (23), we favorthe interpretation that residue 126 represents
a contact site with the T cell receptor, however, further experiments with
truncated and substituted synthetic peptides in a series of B10 H-2-congenic
strains will be required to resolve this question . Examination of the T cell
proliferative response to a third subtype sequence, p120-131adw, which differs
from the ayw sequence at residues 126, 127, 130, and 132, and from the adw2
sequence at residues 127, 130, and 132, emphasized the importance of residue
126, and revealed that residues 127, 130, and 132 were not critical to T cell
recognition. Therefore, we cantentatively localize adominant T cell determinant
on p120-145 to residues 120-126, although the possible influence of residues
128 and 129 cannot be excluded.
Having identified a dominant site on p120-145 recognized by T cells of the
C3H.Q and other strains, we wished to examine the specificity of antibody
produced after p120-145/ayw immunization in C3H.Q mice. In contrast to T
cell recognition, the majority of antibody specific for p120-145 bound to the
COOH-terminal sequence p133-145, and showed ahigh degree of crossreactivity544
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for the adzoz sequence. Furthermore, a large proportion of anti-p120-145
antibody crossreacted with native HBsAg/p33, unlike pl20-145-primed T cells.
Additionally, antibody raised against the p120-132 sequence appeared to rec-
ognize distinct regions of the peptide as compared with T cell recognition. These
results indicate that T and B cell recognition sites can be distinct even on a
synthetic peptide as small as 13 residues. Physical-chemical characterization of
these and other synthetic T and B cell sites within the pre-S region of HBsAg
will be the subject of future studies to determine whether a structure-function
relationship can be identified. In this regard, it has recently been suggested (24,
25) that T cell recognition sites on a protein may be represented by amphipathic
structures displaying periodicity in hydrophobic residues. Note that the sequence
comprising residues 121-135 in the pre-S(2) region fits this amphipathicity
hypothesis (J. A. Berzofsky, personal communication). The pre-S region of
HBsAg may serve as a useful model for comparing T cell and B cell recognition
sites because of the largely sequential (as opposed to conformational) require-
ments for antibody binding to this region (3, 4). This characteristic made it
feasible to define two distinct but overlapping antibody binding sites within the
p133-143 sequence of the pre-S(2) region of HBsAg using synthetic peptides and
mAbs as described elsewhere.'
The results of this study have implications with respect to the development of
completely synthetic vaccines. In view of preliminary experiments suggesting
that antisera to the pre-S(2) region of HBsAg may be protective against HBV
infection, a vaccine exclusively composed of pre-S(2) region determinants could
be contemplated. More likely, pre-S(2) and S region determinants may be
combined in future HBV vaccines. Since the pre-S(2) and S regions exist on the
same polypeptide, this strategy has the additional advantage that a T cell response
to the pre-S(2) region circumvents nonresponsiveness to the S region in S region
nonresponder mice (5). Since the synthetic T cell determinant p120-132 was
capable of priming T cell help for antibody production to the synthetic B cell
determinant p133-145, and since this antibody reacted with the native pre-S(2)
region, this system provides evidence that synthetic T and B cell recognition sites
can be combined to yield a functional immunogen (vaccine). Due to the MHC-
dependent restrictions imposed on T cell recognition of antigen, several T cell
recognition sites or a combination of free and conjugated peptide may be
required to insure responsiveness in a high percentage of vaccine recipients. In
this regard, the p120-132 sequence served as a T cell recognition site in mice
bearing the H-2q,',' haplotypes but not the H-26 haplotype. An ideal synthetic
vaccine will be composed of T and B cell recognition sites identical to those
recognized on the native molecule. Such a vaccine would induce neutralizing
antibody and elicit T and B cell memory relevant to the pathogen in case of a
subsequent infection after neutralizing antibody wanes. A synthetic T cell deter-
minant would also obviate the requirement to conjugate synthetic B cell sites to
a heterologous protein carrier. Although p120-145 may not represent the ideal
synthetic pre-S(2) region immunogen (in mice), it does represent a completely
synthetic and functional immunogen, similar to a peptide-carrier conjugate,
although not requiring the heterologous protein carrier to elicit T cell helper
function. These results, and the identification of T cell recognition sites withinMILICH ET AL.
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the S (26) and pre-S(1) regions of native HBsAg (16) increase, at least concep-
tually, the feasibility of a completely synthetic HBV vaccine.
Summary
We have examined T cell recognition of a hepatitis B surface antigen (HBsAg),
pre-S(2)-region synthetic peptide, p120-145, in terms of fine specificity, H-2-
linked genetic influences, comparison to antibody binding, and relevance to T
cell recognition of the native protein . We showed that the immune response to
the synthetic peptide is regulated by H-2-linked genes, but that the pattern of
H-2 restriction differed from that observed for the native anti-pre-S(2) response.
Dominant and nonoverlapping T cell and B cell recognition sites were identified
on the synthetic peptide p120-145. T cell recognition is focussed on the NH 2-
terminal sequence, and antibody (B cell) recognition is focussed on the 000H-
terminal sequence. The fine specificity of T cell recognition of p120-145 was
defined by a single, subtype-dependent amino acid substitution. With respect to
the immunogenicity of p120-145, the synthetic peptide containing both T and
B cell determinants is highly immunogenic in responder strains, whereas separate
T or B cell peptide determinants are minimally immunogenic. Furthermore, the
synthetic T cell recognition site can prime T cell help for antibody production
to the synthetic B cell site, which is crossreactive with the native pre-S(2) region
of HBsAg/p33 particles. This system provides evidence that totally synthetic T
cell and B cell recognition sites can be combined to yield a functional immunogen .
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